Compugen Ltd (NAS:CGEN)

$ 1.54 0.04 (2.67%) Market Cap: 136.12 Mil Enterprise Value: 25.92 Mil PE Ratio: 51.33 PB Ratio: 2.30 GF Score: 53/100

Q3 2024 Compugen Ltd Earnings Call Transcript
Nov 12, 2024

$1.6 (-8.05%)

Earnings
Q2 2024 Compugen Ltd Earnings Call Transcript
Aug 06, 2024

$1.72 (+4.88%)

Earnings
Q1 2024 Compugen Ltd Earnings Call Transcript
May 20, 2024

$1.74 (-17.54%)

Earnings
Q4 2023 Compugen Ltd Earnings Call Transcript
Mar 05, 2024

$2.55 (-13.56%)

Earnings
Compugen Ltd Corporate Update Call Transcript
Dec 19, 2023
Q3 2023 Compugen Ltd Earnings Call Transcript
Nov 07, 2023

$0.6818 (-5.85%)

Earnings
Compugen Ltd at HC Wainwright Investment Conference - New York Transcript
Sep 11, 2023
Q2 2023 Compugen Ltd Earnings Call Transcript
Aug 07, 2023

$1.03 (-8.04%)

Earnings
Compugen Ltd at JMP Securities Life Sciences Conference Transcript
May 16, 2023
Q1 2023 Compugen Ltd Earnings Call Transcript
May 15, 2023

$0.8144 (+10.02%)

Earnings
Q4 2022 Compugen Ltd Earnings Call Transcript
Feb 27, 2023

$0.7616 (+2.17%)

Earnings
Compugen Ltd At ESMO 2022 Immuno-Oncology Annual Congress Transcript
Dec 07, 2022
Compugen Ltd at JMP Securities Hematology Oncology Summit (Virtual) Transcript
Dec 06, 2022
Compugen Ltd at Stifel Healthcare Conference Transcript
Nov 15, 2022
Q3 2022 Compugen Ltd Earnings Call Transcript
Nov 14, 2022

$0.8347 (-9.27%)

Earnings
Q2 2022 Compugen Ltd Earnings Call Transcript
Aug 04, 2022

$1.55 (-4.32%)

Earnings
Compugen Ltd at JMP Securities Life Sciences Conference Transcript
Jun 15, 2022
Q4 2021 Compugen Ltd Earnings Call Transcript
Feb 24, 2022

$2.93 (+6.16%)

Earnings
Q3 2021 Compugen Ltd Earnings Call Transcript
Nov 12, 2021

$5.87 (-18.02%)

Earnings
Compugen Ltd at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript
Sep 30, 2021
Compugen Ltd at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 09, 2021
Q2 2021 Compugen Ltd Earnings Call Transcript
Jul 28, 2021

$6.88 (+7.84%)

Earnings
Q1 2021 Compugen Ltd Earnings Call Transcript
May 13, 2021

$7.41 (+7.86%)

Earnings
Q4 2020 Compugen Ltd Earnings Call Transcript
Feb 25, 2021

$8.96 (-13.51%)

Earnings
Compugen Ltd at Evercore ISI HealthCONx Conference Transcript
Dec 01, 2020
Compugen Ltd at Jefferies Virtual London Healthcare Conference Transcript
Nov 18, 2020
Compugen Ltd at Stifel Virtual Healthcare Conference Transcript
Nov 17, 2020
Q3 2020 Compugen Ltd Earnings Call Transcript
Nov 05, 2020

$14.11 (+3.67%)

Earnings
Compugen Ltd at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Virtual) Transcript
Sep 22, 2020
Compugen Ltd at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 16, 2020
Q2 2020 Compugen Ltd Earnings Call Transcript
Jul 30, 2020

$15.44 (+8.12%)

Earnings
Q1 2020 Compugen Ltd Earnings Call Transcript
May 06, 2020

$13.22 (-10.13%)

Earnings
Q4 2019 Compugen Ltd Earnings Call Transcript
Feb 20, 2020

$10.51 (+7.46%)

Earnings
Q3 2019 Compugen Ltd Earnings Call Transcript
Nov 11, 2019

$5.43 (+0.56%)

Earnings
Q2 2019 Compugen Ltd Earnings Call Transcript
Aug 05, 2019

$3.01 (-5.35%)

Earnings
Q1 2019 Compugen Ltd Earnings Call Transcript
May 20, 2019

$3.45 (-0.29%)

Earnings
Q4 2018 Compugen Ltd Earnings Call Transcript
Feb 26, 2019

$3.12 (-17.02%)

Earnings

Q3 2022 Compugen Ltd Earnings Call Transcript

Nov 14, 2022 / 01:30PM GMT

Release Date Price: $0.8347 (-9.27%)

Transcript

Operator

Ladies and gentlemen, thank you for joining us today. Welcome to Compugen's Third Quarter 2022 Results Conference Call. (Operator Instructions) An audio webcast of this call is available in the Investors section of Compugen's website, www.cgen.com. As a reminder, today's call is being recorded.

I would now like to introduce Yvonne Naughton, Head of Investor Relations and Corporate Communications. Yvonne, please go ahead.

Yvonne Naughton

Compugen Ltd. - Head of IR & Corporate Communications

Thank you, Jamie, and thank you all for joining us on the call today. Joining me from Compugen are Dr. Cohen-Dayag, President and Chief Executive Officer; Dr. Henry Adewoye, Chief Medical Officer; Dr. Eran Ophir, Senior Vice President Research and Drug Discovery; and Alberto Sessa, Chief Financial Officer.

Before we begin, we would like to remind you that during this call, the company may make projections or forward-looking statements regarding future events, business outlook, development

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.